Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $8.8 million.

  • Celldex Therapeutics' Share-based Compensation fell 851.35% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 1709.29%. This contributed to the annual value of $34.2 million for FY2024, which is 4333.19% up from last year.
  • As of Q3 2025, Celldex Therapeutics' Share-based Compensation stood at $8.8 million, which was down 851.35% from $9.2 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Share-based Compensation registered a high of $9.8 million during Q4 2024, and its lowest value of $1.3 million during Q1 2021.
  • Its 5-year average for Share-based Compensation is $5.8 million, with a median of $5.2 million in 2023.
  • In the last 5 years, Celldex Therapeutics' Share-based Compensation surged by 14980.11% in 2021 and then crashed by 851.35% in 2025.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Share-based Compensation stood at $3.1 million in 2021, then soared by 43.57% to $4.5 million in 2022, then soared by 59.98% to $7.2 million in 2023, then surged by 35.61% to $9.8 million in 2024, then fell by 10.01% to $8.8 million in 2025.
  • Its Share-based Compensation was $8.8 million in Q3 2025, compared to $9.2 million in Q2 2025 and $9.3 million in Q1 2025.